Back

Cardiovascular adverse events after CAR-T, BiTEs and TILs therapies: a systematic review and meta-analysis

21 June 2025 (08:00 - 18:00)
Organised by: Logo
Congress Presentation Part of: Poster session (2) Cardio-Oncology CCO Premium Access ESC Cardio-Oncology 2025 Council of Cardio-Oncology

About the speaker

Photo
Doctor Rodrigo Carrasco

University Hospital Zurich, Zurich (Switzerland)

59 More presentations in this session

Presentation thumbnail
Temporal trends and emerging burden of cardiovascular disease in cancer patients: A nationwide study from 2005 to 2022
Doctor J. Cho (Daejeon, KR)
Abstract
Presentation thumbnail
Cardiovascular risk factors in oncology: A cross-sectional analysis of patients undergoing chemo-radiotherapy at a tertiary care center
Doctor M. Canavera Ibanez (Bogota, CO)
Abstract Slides
Presentation thumbnail
Incidence of acute cardiovascular hospitalizations and association with hemodynamic biomarkers in cancer patients treated with Immune Checkpoint Inhibitor therapy
Doctor A. Spannbauer (Vienna, AT)
Abstract Slides
Presentation thumbnail
Cardiovascular toxicity prediction in breast cancer patients: the HFA/ICOS risk tool in real-world practice
Doctor B. Andrade (Santarem, PT)
Abstract
Presentation thumbnail
Use of CMR in the assessment of cardiovascular reserve in patients treated with CAR-T therapy
Doctor B. Aumente Rodriguez (Salamanca, ES)
Abstract Slides

Access the full session

Session thumbnail
Poster session (2)

The Event

Event poster

ESC Cardio-Oncology 2025

21 June 2025 08:00 CET
You may be interested in
thumbnail
Congress Presentation
Cardiovascular complications of chimeric antigen receptor (CAR)-t cell therapy: insights from a regional cardio-oncology program
thumbnail
Congress Presentation
Right ventricular dysfunction in hematologic patients exposed to Chimeric Antigen Receptor (CAR)-T cells therapy: results from the prospective CARdio-TOX study.
thumbnail
Congress Presentation
Immune-related cardiovascular adverse events in a real-world cohort of patients treated with immune checkpoint inhibitors

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources